| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC1985 |
| Trial ID | NCT03691376 |
| Disease | Peritoneal Carcinoma | Ovarian Carcinoma | Fallopian Tube Carcinoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| Co-treatment | Melphalan |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| Year | 2018 |
| Country | United States |
| Company sponsor | Roswell Park Cancer Institute |
| Other ID(s) | i 287616|NCI-2018-01758|i 287616 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||